Janelle Hart

In a recent interview, Kevin T. McVary, MD, FACS, suggested that more physicians should take the time to educate their themselves and their patients on enlargement of the prostate.

Results also showed that Black men were 29% more likely to be diagnosed with prostate cancer using a diagnostic prostate biopsy vs White men.

“Our team showed that treating a group of approximately 10 to 15 men with hormone therapy or extended adjuvant hormone therapy, for at least 18 months, prevented one man from developing metastatic disease 10 years after treatment," says Daniel E. Spratt, MD.

"This analysis of this publication confirms the link between efficacy and the patient perception, and that the results are actually meaningful to the patients as well," says Cornelia Haag-Molkenteller, MD, PhD.

"Our analysis suggests that a warming planet will likely cause an increased burden of kidney stone disease on health care systems,” says Gregory E. Tasian, MD, MSc, MSCE.

“Our findings underscore the need to study patterns of e-cigarette use that are relatively safer than smoking,” said lead author Omar El Shahawy, MD, PhD, MPH.

This study underscores how common urinary incontinence is in women, with nearly 1 in 5 Japanese women reporting urinary incontinence related to OAB or SUI in the last month,” said Stephanie Faubion, MD, MBA, medical director of the North American Menopause Society.

In this interview, Curtis A. Pettaway, MD, reflects on what innovations and research led to his becoming the first Black recipient of the Society of Urologic Oncology’s Huggins Award.

The improved response to radiotherapy was observed despite Black men having more aggressive disease at enrollment.

In a recent interview, Geolani Dy, MD, and Gaines Blasdel gave an overview of the gap in urologic care of gender diverse people and what urologists can do to make their practices more accessible to transgender patients.

Badar M. Mian, MD, FACS, discusses advantages and limitations of transperineal prostate biopsy and highlights ongoing research with this newer modality.

In this interview, Kelvin A. Moses, MD, PhD, FACS, provides insight on how clinicians may be able to help patients with prostate cancer address the financial burden of the disease.

At a median follow-up of 10.4 months (IQR: 5.8-16.4), SAbR extended drug efficacy by more than 6 months in 70% of mRCC patients (14 out of 20; 95% CI: 49.9-90.1).

"I was very early among the first women in urology, and in those days it was really going out on a limb to go into that field," said Eila C. Skinner, MD.

A retrospective analysis of the phase 3 CheckMate-214 trial showed a treatment-free survival advantage with the immunotherapy combination versus the targeted therapy sunitinib in patients with advanced renal cell carcinoma.

As an advocate for patients, Svetlana Avulova, MD, stresses the importance of this population of women with bladder cancer and how their desire to preserve sexual function through organ-sparing treatment should be recognized and validated.

Gerald L. Andriole, MD, and co-authors recently presented a study at the 2021 Society of Urologic Oncology Annual Meeting that investigates the novel imaging modality 18F-Fluciclovine PET scan for patients with biochemically recurrent prostate cancer.

A recent study, co-authored by Karim Sultan Haider, MD, explored the long-term effects of testosterone therapy on erectile function and mortality in hypogonadal men and men with diabetes.

At the 2021 SUO Annual Meeting, Andrew J. Armstrong, MD, MSc, presented promising findings from the study, “The efficacy of enzalutamide (Enza) plus androgen deprivation therapy (ADT) on oligometastatic hormone-sensitive prostate cancer: extended post hoc analysis of ARCHES.”

In a recent study, Michael Palese, MD, Evan Garden, and co-authors estimated the long-term outcomes of Rezum water vapor therapy in treating men with large prostates who have benign prostatic hyperplasia.

Peter N. Schlegel, MD, discusses why male infertility should be normalized not only in the field of urology, but throughout society.

The impact of the VISION trial, a study investigating prostate-specific membrane antigen (PSMA)-targeted therapy for advanced prostate cancer, was discussed in a talk presented by Michael J. Morris, MD, at the 2021 Society of Urologic Oncology Annual Meeting.

At the 2021 Society of Urologic Oncology Annual Meeting, Alexander Kutikov, MD, FACS, gave a presentation on determining and helping improve the negative predictive value of cystoscopy in ruling out muscle invasive bladder cancer.

A study presented at the 2021 Society of Urologic Oncology Annual Meeting investigated adjuvant nivolumab in a population of patients with high risk of disease recurrence after radical surgery.

At the 2021 Society of Urologic Oncology Annual Meeting, a study was presented by Siv Venkat, MD, FRCSC, that evaluates the outcomes of the bladder-sparing method of segmental ureterectomy versus radical nephroureterectomy.

In this interview, Wesley Yip, MD, discusses the feasibility and validation of genomic profiling of upper tract urothelial carcinoma from urine cytology specimens.

Isla Garraway, MD, PhD, discusses the potential for expanding the range of men with early prostate cancer who can receive active surveillance.

"I'm hopeful and optimistic that over the next couple of years, we have some really reliable biomarkers to utilize in these patients who we know have frequent recurrences,"says Kristen Scarpato, MD, MPH.

"I think that we have seen a lot of updates and advances in advanced prostate cancer generally, one of the biggest of these being PSMA-targeted lutetium," says Alicia K. Morgans, MD, MPH.

"It's comforting to know that the vast majority of patients will meet criteria for [lutetium PSMA], and therefore hopefully be able to receive that type of therapy," says Scott. T. Tagawa, MD, MS, FACP.